secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surgery Partners, Inc. (SGRY)
CIK:        0001638833
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001638833-26-000006
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surgery Partners Q4 rev $885M (+2.4%), Adj. EBITDA $156.9M (-4.2%), net loss $15M, 2026 guidance, $200M buyback
--------------------------------------------------------------------------------

- Revenue $885.0M (+2.4% YoY); full-year $3.3B (+6.2%). Same-facility revenue +3.5% Q4.
- Adj. EBITDA $156.9M (-4.2% YoY); full-year $526.2M (+3.5%). Net loss $15.0M Q4, $77.9M FY.
- 2026 guidance: Adj. EBITDA at least $530M; revenue range $3.35B-$3.45B.
- Board authorized $200M share repurchase program on February 26, 2026.
- Operating cash flow $103.4M Q4 (down from $111.4M); net debt/EBITDA ~4.3x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638833/000163883326000006/0001638833-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638833/000163883326000006/sgry-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001638833-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer